[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"informed-consent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:informed-consent":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,53,75,106,150,187,216,245,268,295,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100651626","physician-vs-artificial-intelligence-counseling-before-elective-cesarean-delivery-a-randomized-controlled-trial-100651626",false,"NCT07762534","Physician vs Artificial Intelligence Counseling Before Elective Cesarean Delivery: A Randomized Controlled Trial","A Randomized Controlled Trial Comparing Physician-Provided Versus Artificial Intelligence-Based Preoperative Counseling Before Elective Cesarean Delivery","CAI-CS","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Singleton pregnancy\n* Third trimester of pregnancy\n* Scheduled for elective cesarean delivery\n* Full proficiency in written and spoken Hebrew\n\nExclusion Criteria:\n\n* Non-elective cesarean delivery (urgent or emergency cesarean delivery) that does not allow completion of the counseling process and study questionnaires\n* Known anxiety disorder or depression\n* Cognitive impairment\n* Insufficient Hebrew language proficiency to independently complete study questionnaires\n* Multiple gestation pregnancy\n* Known fetal anomaly or significant fetal pathology diagnosed before delivery","FEMALE","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial will compare two methods of providing preoperative counseling before elective cesarean delivery: counseling by an obstetrician-gynecologist and counseling delivered through an artificial intelligence (AI)-based system. The study aims to evaluate the effects of these counseling methods on patients' anxiety levels, understanding of medical information, and satisfaction with the counseling process.\n\nWomen scheduled for elective cesarean delivery will be randomly assigned to receive either standard physician counseling or AI-based counseling containing the same medical information. Anxiety, knowledge, and satisfaction will be assessed using questionnaires before and after counseling.",[27,28,29],"Cesarean Section","Informed Consent","Anxiety",[31,27,32,33,28,34,35,29,36,37,38,39],"Elective Cesarean Delivery","Artificial Intelligence","AI Counseling","Preoperative Counseling","Patient Education","STAI","Shared Decision Making","Patient Satisfaction","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-08-08",{"date":43,"type":44},"2026-08-13","ACTUAL",{"date":46,"type":21},"2026-08-20",{"date":48,"type":21},"2027-08-01",{"name":50,"class":51},"Wolfson Medical Center","OTHER_GOV",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":52},"100650941","chatbot-implementation-in-the-clinical-informed-consent-process-100650941","NCT07756515","Chatbot Implementation In The Clinical Informed Consent Process","Inclusion Criteria:\n\n* Ability to understand and willingness to provide informed consent.\n* Age ≥18 years.\n* Patients whose preferred language is English.\n* Patients who are being considered for enrollment in selected clinical research studies.\n\nPhase I will be initiated using the Clearinghouse protocol PA11-0852, a non-interventional biomarker study.\n\nExclusion Criteria:\n\nN\u002FA","ALL",{"count":61,"type":21},100,[24],"The purpose of this study is to determine the feasibility of implementing the chatbot \"CoCo\" in the IC process for research studies. We hypothesize that implementing a chatbot into the IC process will facilitate accurate information delivery and enhance participant comprehension and process satisfaction compared to traditional remote consent methods.",[28],"2026-08-07",{"date":67,"type":44},"2026-08-10",{"date":69,"type":21},"2027-01-01",{"date":71,"type":21},"2031-12-17",{"name":73,"class":74},"M.D. Anderson Cancer Center","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100530878","implementing-a-novel-consent-process-for-biospecimen-research-after-newborn-screening-100530878","NCT06192511","Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening","Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening in Hospitals Serving Diverse Patients","MICI","Inclusion Criteria:\n\n* Adult (\\> 18 years)\n* English, Spanish or Arabic speaking\n* Just gave birth and currently a patient in the Mother \\& Baby Unit in the hospital\n\nExclusion Criteria:\n\n* Parents of infants who are born pre-term (\\\u003C 37 weeks gestation)\n* Parents of infants in the Neonatal Intensive Care Unit\n* Parents of infants being put up for adoption or in situations where legal guardianship is unknown at the time of birth",true,{"count":85,"type":21},5980,[24],"The purpose of this study is to implement an electronic consent education process for the retention and research use of residual dried bloodspots at four hospitals in Michigan and assess the impact of the new education, both on patients and hospital staff. The research team will recruit women who have just given birth to answer surveys about the Michigan BioTrust consent process. Surveys will be collected from participants in the hospital and again four weeks later. The research team will collect survey data from patient participants at each hospital prior to hospital staff implementation of the new education process and again after staff implementation.",[89,28,90],"Implementation Science","Neonatal Screening",[92,93,94],"newborn screening","informed consent","biobanking","RECRUITING","2026-07-29",{"date":98,"type":44},"2026-07-31",{"date":100,"type":44},"2024-05-15",{"date":102,"type":21},"2028-04-30",{"name":104,"class":74},"Erin Rothwell",2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":128,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100635793","supporting-just-in-time-consent-for-prenatal-screening-the-inform-study-100635793","NCT07557303","Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study","Inclusion Criteria:\n\n* Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.\n* 18 years of age and older\n* Able to read, speak, and understand English or Spanish\n* Has not previously been offered prenatal genetic screening for the current pregnancy\n* 24 weeks (6 months) gestational age or less\n\nExclusion Criteria:\n\n* Not pregnant, not a patient at a partner clinical site\n* Younger than 18 years of age\n* Not being able to read, speak, and understand English or Spanish\n* Has previously been offered prenatal genetic screening for the current pregnancy\n* Greater than 24 weeks gestational age (6 months)",{"count":113,"type":21},1400,[24],"This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.\n\nThe study has one main question:\n\n* Do participants who use the intervention feel more confident when they make a decision about screening?\n\nResearchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.\n\nWhat will participants do?\n\n* Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.\n* Some participants will use the intervention before their first doctor's visit. Other participants will not use it.\n* All participants will talk with a researcher on the phone after their first doctor's visit.\n* Participants who use the intervention will answer a short survey on their phone.\n* A few participants who use the intervention will talk with a researcher a second time on the phone.",[117,118,119,120,121,28,122,123,124,125,126,127],"Delivery of Health Care","Genetic Testing","Humans","Pregnancy","Noninvasive Prenatal Testing","Internet-Based Intervention","Self Efficacy","Pregnant People","Decision Making","Health Education","Patient Education as Topic\u002FMethod",[129,130,131,132,133,134,135,136,137,138,139],"Non-invasive prenatal screening (NIPS)","Non-Invasive Prenatal Testing (NIPT)","Cell-free DNA (cfDNA)","Prenatal genetic screening","Informed consent","Decision making","Surveys and Questionnaires","Informed choice","Educational intervention","Decision Regret","Decision Satisfaction","2026-07-22",{"date":142,"type":44},"2026-07-23",{"date":144,"type":21},"2026-08-01",{"date":146,"type":21},"2028-06-30",{"name":148,"class":74},"Case Western Reserve University",3,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":166,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":52},"100648462","digital-supported-versus-standard-consent-for-advanced-therapeutic-endoscopy-100648462","NCT07723105","Digital-Supported Versus Standard Consent for Advanced Therapeutic Endoscopy","Digital-Supported Versus Standard Informed Consent for Advanced Therapeutic Endoscopy: A Pragmatic Multicenter Randomized Trial","DIGI-CONSENT","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo elective advanced therapeutic endoscopy\n* Able to provide informed consent for study participation\n* Able to engage with study materials in a language supported by the site\n* Willing and able to complete study questionnaires and follow-up assessments\n\nExclusion Criteria:\n\n* Emergent or urgent procedures where the consent process cannot reasonably incorporate the study intervention\n* Inability or unwillingness to provide informed consent for study participation\n* Requirement for substitute decision-maker consent for the procedural decision itself, if this precludes meaningful use of the study intervention\n* Severe cognitive, visual, hearing, or communication limitations not adequately accommodated by site resources\n* Inability to complete the planned pre-procedural assessments\n* Prior enrollment in this study for the same procedural episode\n* Any clinical situation in which the treating endoscopist determines that study participation would be unsafe or inappropriate",{"count":159,"type":21},180,[24],"This study will evaluate whether a digital-supported informed consent process improves patient understanding before advanced therapeutic endoscopy procedures.\n\nPatients undergoing advanced therapeutic endoscopy are often asked to make decisions about procedures that may be complex and involve important risks, benefits, and alternatives. Standard informed consent is usually provided through discussion with the treating physician. However, this process can vary between clinicians and may be affected by time pressures in busy endoscopy units.\n\nIn this study, eligible adult patients scheduled for elective advanced therapeutic endoscopy will be randomly assigned to one of two consent pathways. One group will receive standard physician-led informed consent. The other group will receive a digital-supported consent pathway that includes a standardized procedure-specific educational video, an offline artificial intelligence-based question-answering tool, and final confirmation with the treating physician before the procedure.\n\nThe digital tool is designed to provide plain-language information about the procedure, including why it is being done, expected benefits, common and serious risks, alternatives, what to expect before and after the procedure, and the patient's right to ask questions or decline the procedure. The AI question-answering tool will use only investigator-approved educational content and will not provide individualized medical advice. Questions requiring patient-specific medical judgment will be directed back to the treating clinical team.\n\nThe main outcome of the study is patient comprehension of the consent information, measured after the assigned consent process and before the procedure. The study will also evaluate patient anxiety, satisfaction, confidence in decision-making, usability of the consent process, workflow outcomes, and consent-related safety or ethical concerns.",[28,35,163,164,165],"Patient Comprehension","Therapeutic Endoscopy","Digital Health",[167,133,168,169,170,171,172,173,174,175,176,177,178],"Digital consent","Advanced endoscopy","Therapeutic endoscopy","Patient comprehension","Patient education","Artificial intelligence","AI question-answering tool","Video-based consent","Patient satisfaction","Pre-procedural anxiety","Pragmatic randomized trial","Endoscopy workflow","2026-07-20",{"date":142,"type":44},{"date":182,"type":21},"2026-09-01",{"date":184,"type":21},"2028-03-01",{"name":186,"class":74},"Unity Health Toronto",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":52},"100645186","consent-understanding-and-propofol-requirement-during-endobronchial-ultrasound-100645186","NCT07677982","Consent Understanding and Propofol Requirement During Endobronchial Ultrasound","Association of Preoperative Consent Understanding With Propofol Requirement During Endobronchial Ultrasound: A Prospective Observational Study","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for elective endobronchial ultrasound\n* ASA physical status I to III\n* Ability to read and understand Turkish\n* Provision of written informed consent for study participation\n\nExclusion Criteria:\n\n* Active psychiatric disease that may affect the informed consent process, anxiety assessment, or communication\n* Cognitive impairment, including dementia or delirium\n* Contraindication or known allergy to propofol, midazolam, or remifentanil\n* Emergency EBUS procedure\n* Regular anxiolytic or sedative drug use within the last month\n* Illiteracy\n* Turkish language barrier\n* Advanced organ failure or decompensated systemic disease that may significantly affect sedative drug response, hemodynamic stability, communication, or consent assessment",{"count":195,"type":21},75,"OBSERVATIONAL","The goal of this observational study is to learn whether a participant's understanding of the informed consent information is related to the amount of propofol needed during endobronchial ultrasound (EBUS). EBUS is a procedure that uses a thin camera and ultrasound to look at lymph nodes and other areas inside the chest. Propofol is a sedative medicine used to help participants stay comfortable during the procedure.\n\nBefore EBUS, all participants will receive the usual information about the procedure as part of routine care. After this routine consent process, participants will answer short questions about what they understood. They will also answer questions about their anxiety before the procedure. The study will not change the usual consent process, sedation plan, or medical care.\n\nDuring EBUS, participants will receive usual sedation and monitoring according to routine clinical practice. The research team will record how much sedative medicine is used, whether extra sedation is needed, whether any important clinical events occur, and how participants recover after sedation. The main question is whether participants who understand the consent information better need less propofol during EBUS.",[199,200,28],"ENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION","Procedural Sedation and Analgesia",[202,203,204,205,206,207],"EBUS-TBNA","Informed consent understanding","Procedural sedation","Preoperative anxiety","Sedative requirement","Propofol consumption","2026-06-30",{"date":210,"type":44},"2026-07-01",{"date":210,"type":21},{"date":213,"type":21},"2027-07-01",{"name":215,"class":74},"Uludag University",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":83,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":226,"conditions":227,"keywords":231,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":52},"100616277","ai-driven-consent-simplification-study-100616277","NCT07303517","AI-Driven Consent Simplification Study","ACCESS: AI-Driven Consent Simplification Study","ACCESS","Inclusion Criteria:\n\nGroup 1:\n\n* Age 60 years and above\n* UCLA patient\n* English speaking\n* Ability to provide informed consent\n\nGroup 2:\n\n* UCLA investigators who are health providers that perform clinical trials\n* Must be clinical research investigatory and staff actively involved in research operations at UCLA\n* English speaking\n\nGroup 3:\n\n* Individuals involved in IRB activities (chairs, committee members, staff)\n* Must be a director or staff at UCLA\n* English speaking\n\nExclusion Criteria:\n\n* Group 1: None\n* Group 2: PI and co-PIs of the study \"Donor Chimerism and Graft Survival Following Combined HLA-Identical Sibling Living Donor Kidney and Hematopoietic Stem Cell Transplantation Utilizing a Conditioning Regimen of Total Lymphoid Irradiation (TLI) and Rabbit Anti-Thymocyte Globulin (rATG)\"\n* Group 3: Individuals from the IRB who have reviewed the study submission for \"Donor Chimerism and Graft Survival Following Combined HLA-Identical Sibling Living Donor Kidney and Hematopoietic Stem Cell Transplantation Utilizing a Conditioning Regimen of Total Lymphoid Irradiation (TLI) and Rabbit Anti-Thymocyte Globulin (rATG)\"",{"count":225,"type":21},230,"The overarching goal of this pilot is to explore how generative artificial intelligence (genAI) can be used to improve the accessibility and understandability of informed consent materials in clinical research. The study will test the extent to which informed consent text can be improved by large language models (LLM; specifically, ChatGPT and NotebookLM) along with other AI tools (specifically, ElevenLabs) through qualitative and quantitative analyses.\n\nSimplifying such forms using genAI may facilitate better comprehension, ensuring truly informed consent. Improving informed consent form (ICF) comprehension can lead to more informed and willing participation in clinical studies. This improved understanding may result in higher enrollment rates, better subject retention, and more accurate data collection as individuals will have a clearer understanding of study procedures and risks.",[28,228,229,230],"Comprehension","Communication","Disclosure",[232,233,234,235],"Informed Consent Readability","Plain language","Simplified consent forms","Research ethics","2026-05-04",{"date":238,"type":44},"2026-05-08",{"date":240,"type":44},"2026-01-08",{"date":242,"type":21},"2026-12-01",{"name":244,"class":74},"University of California, Los Angeles",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":52},"100601992","optimizing-timing-of-cesarean-delivery-consent-on-labor-and-delivery-100601992","NCT07117708","Optimizing Timing of Cesarean Delivery Consent on Labor and Delivery","The Optimize Trial: Optimizing Timing of Cesarean Delivery Consent on Labor and Delivery","Inclusion Criteria:\n\n* 18 years of age or older\n* Receiving prenatal care at Duke Perinatal Durham or Duke Women's Health Associates\n* Between 34 weeks 0 days and 41 weeks 0 days of gestation\n* Scheduled for induction of labor OR are eligible\u002Fintend to be scheduled for an induction of labor\n\nExclusion Criteria:\n\n* Trial of labor after cesarean delivery\n* Multiple gestation\n* Major fetal anomalies\n* Presenting for induction of labor as a transfer from the antepartum inpatient service\n* Non-English speaking\n* Those who do not intend to labor\n* Patients who are ineligible for vaginal delivery for other reasons, including fetal malpresentation or abnormal placentation",{"count":253,"type":21},200,[24],"Nationally, 32.1% of pregnant patients deliver via cesarean delivery, including both patients who undergo a planned cesarean delivery and patients who intend to undergo vaginal delivery and are recommended to deliver via cesarean delivery. The investigators aim to understand how to optimize the patient experience for patients who present to the hospital intending to deliver vaginally but are recommended to deliver via cesarean delivery (an unplanned cesarean delivery). Practices regarding timing of informed consent for possible cesarean delivery vary widely across hospitals in the United States; some institutions will consent every patient on admission to the hospital for possible cesarean delivery, whereas some institutions consent patients for possible cesarean delivery only if a patient's clinical course suggests cesarean delivery may be indicated.\n\nThis study aims to determine optimal timing for consent for possible cesarean delivery by randomizing patients to either be consented for possible cesarean delivery on admission to the hospital or if it appears to be clinically indicated. This study will only assess altered timing of a surgical consent process and will not impact the clinical care participants receive. After delivery, participants will share their experiences with the consent process and with their overall childbirth experience.",[120,28],[258,93],"pregnancy","2026-04-22",{"date":261,"type":44},"2026-04-23",{"date":263,"type":44},"2025-08-27",{"date":265,"type":21},"2027-05",{"name":267,"class":74},"Duke University",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":52},"100584796","patient-preferences-on-same-day-bilateral-intravitreal-dexamethasone-injections-100584796","NCT06894017","Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections","Inclusion criteria\n\n* Having received at least one intravitreal dexamethasone implant in either eye\n* \\>18 years of age\n* Capacity to comprehend and answer questions in Danish language\n* Signed informed consent\n\nExclusion criteria\n\n• No intravitreal dexamethasone implant received within the last 12 months",{"count":253,"type":21},"Intravitreal injections with dexamethasone implant (Ozurdex®) provide a reasonable and long-lasting treatment option in the cases of diabetic macular edema, as well as macular edema resulting from retinal vein occlusion and noninfectious posterior uveitis. During the course of these diseases, both eyes may be affected and may need therapy. The treatment burden associated with frequent medical visits associated with treatments in both eyes and follow-ups can be significant for patients and caregivers alike. Same-session bilateral ophthalmic procedures have proven safe and cost-effective, with patients consistently expressing a strong preference for this approach, particularly in the cases of cataract surgery and anti-VEGF injections when given the choice. The safety profile of same-day bilateral dexamethasone injections aligns with those of unilateral injections.\n\nThis patient preference study will focus on addressing the practical aspects of same-day bilateral dexamethasone injections from the patients' perspective and aims to explore the impact of personal and socio-economic variables, and the overall perspective of patients on choosing same-day bilateral dexamethasone injections. Understanding and mitigating the challenges patients face can lead to a more patient-friendly and resource-saving approach. Based on the outcomes of this study, considerations may be made to introduce bilateral injections at our department, potentially optimizing patient experience and clinical resources.\n\nThe aim of the study is to establish patient preferences regarding the administration of intravitreal dexamethasone implant injections in both eyes on the same day, in the same session and to identify key motivating and limiting factors from the patients' perspective.",[28,277],"Preference, Patient",[279,280,281,282,283,284,285],"Intravitreal","dexamethasone","injections","implant","questionnaire","patient preference","bilateral","2025-07-22",{"date":288,"type":44},"2025-07-24",{"date":290,"type":44},"2025-01-13",{"date":292,"type":21},"2026-01",{"name":294,"class":74},"Rigshospitalet, Denmark",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":83,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100580613","effectiveness-of-immersive-virtual-reality-in-nursing-students-learning-100580613","NCT06839573","Effectiveness of Immersive Virtual Reality in Nursing Students' Learning","Effectiveness of Immersive Virtual Reality to Improve Learning Outcomes in Nursing Degree Students: A Randomized Clinical Trial","UBUJIRV25","Inclusion Criteria:\n\n\\- having completed the scheduled in-person simulation in previous years of the degree .\n\nExclusion Criteria:\n\n-the student does not sign the informed consent to participate in the study.",{"count":304,"type":21},140,[24],"Teaching using VR for basic cardiopulmonary resuscitation and patient examination (experimental group) will not result in differences in knowledge and skill acquisition compared to traditional classroom-based simulation teaching (control group), but it will lead to greater satisfaction and self-confidence. Open, single-center randomized clinical trial involving fourth-year nursing degree students at a public university. Participants will be assigned based on their usual teaching groups (ratio of 6-8 students per instructor) and, according to randomization, will receive a 1:1 assignment to either the control group (classroom-based simulation teaching) or the experimental group (classroom-based simulation teaching combined with VR headset teaching). The CONSORT checklist will be followed to report the study.",[28],[309,310,311,312],"Virtual reality","nursing students","Learning Outcomes","Inmersive virtual reality","2025-02-19",{"date":315,"type":44},"2025-02-21",{"date":317,"type":21},"2025-03-05",{"date":319,"type":21},"2025-05-08",{"name":321,"class":74},"Universitat Jaume I",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":4},"100497059","analysis-of-the-persistence-reservoir-and-hiv-latency-100497059","NCT05752318","Analysis of the Persistence, Reservoir and HIV Latency","APRIL Study: Analysis of the Persistence, Reservoir and HIV Latency","APRIL","Inclusion Criteria:\n\n* HIV-infection\n* Adults (\\>18 years)\n* Social insurance\n* Informed consent\n\nExclusion Criteria:\n\n* HIV-uninfected\n* \\\u003C18 years\n* Lack of social insurance\n* Lack or withdraw of consent",{"count":331,"type":21},500,"The APRIL study aims at analyzing HIV reservoirs, latency and persistence on antiretroviral therapy. It enrolls HIV-infected adults providing blood samples of which peripheral blood mononuclear cells are stored. The frequency, phenotype and inducibility of HIV-infected cells are then analyzed. These parameters may vary across the different clinical and therapeutic settings.",[334,28],"HIV Infected Individuals",[336,337,338,339],"HIV","Reservoir","Latency","Persistence","2023-02-28",{"date":342,"type":44},"2023-03-02",{"date":344,"type":21},"2023-02-27",{"date":346,"type":21},"2027-02-25",{"name":348,"class":74},"University Hospital, Strasbourg, France"]